دورية أكاديمية
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
| العنوان: | Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases |
|---|---|
| المؤلفون: | Lupi, Isabella, Brancatella, Alessandro, Cosottini, Mirco, Viola, Nicola, Lanzolla, Giulia, Sgrò, Daniele, Dalmazi, Giulia Di, Latrofa, Francesco, Caturegli, Patrizio, Marcocci, Claudio |
| المساهمون: | Lupi, Isabella, Brancatella, Alessandro, Cosottini, Mirco, Viola, Nicola, Lanzolla, Giulia, Sgrò, Daniele, Dalmazi, Giulia Di, Latrofa, Francesco, Caturegli, Patrizio, Marcocci, Claudio |
| سنة النشر: | 2019 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| مصطلحات موضوعية: | ACTH, Adenocarcinoma, Adult, Asthenia, Atezolizumab, Autoimmune disorder, Autoimmune hypophysiti, CT scan, Cortisol, Diabetes mellitus type 1, Diabetic ketoacidosi, FSH, Fatigue, Female, Fludrocortisone, Glucocorticoid, Glucose (blood), Gonadotrophin, Gonadotropin, HLA genotyping, Headache, Hydrocortisone, Hyperglycaemia, Hypergonadotropic hypogonadism, Hyperkalaemia, Hypoadrenalism, Hypogonadism, Hyponatraemia, Hypophysiti |
| الوقت: | 2019 |
| الوصف: | Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen 4/B7 (CTLA-4/B7) pathways are key regulators in T-cell activation and tolerance. Nivolumab, pembrolizumab (PD-1 inhibitors), atezolizumab (PD-L1 inhibitor) and ipilimumab (CTLA-4 inhibitor) are monoclonal antibodies approved for treatment of several advanced cancers. Immune checkpoint inhibitors (ICIs)-related hypophysitis is described more frequently in patients treated with anti-CTLA-4; however, recent studies reported an increasing prevalence of anti-PD-1/PD-L1-induced hypophysitis which also exhibits slightly different clinical features. We report our experience on hypophysitis induced by anti-PD-1/anti-PD-L1 treatment. We present four cases, diagnosed in the past 12 months, of hypophysitis occurring in two patients receiving anti-PD-1, in one patient receiving anti-PD-1 and anti-CTLA-4 combined therapy and in one patient receiving anti-PD-L1. In this case series, timing, clinical presentation and association with other immune-related adverse events appeared to be extremely variable; central hypoadrenalism and hyponatremia were constantly detected although sellar magnetic resonance imaging did not reveal specific signs of pituitary inflammation. These differences highlight the complexity of ICI-related hypophysitis and the existence of different mechanisms of action leading to heterogeneity of clinical presentation in patients receiving immunotherapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31610523; info:eu-repo/semantics/altIdentifier/wos/WOS:000489783300001; volume:2019; journal:ENDOCRINOLOGY, DIABETES & METABOLISM CASE REPORTS; http://hdl.handle.net/11568/1017035Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85076233658 |
| DOI: | 10.1530/EDM-19-0102 |
| الإتاحة: | https://doi.org/10.1530/EDM-19-0102Test http://hdl.handle.net/11568/1017035Test |
| رقم الانضمام: | edsbas.C4A680CD |
| قاعدة البيانات: | BASE |
| DOI: | 10.1530/EDM-19-0102 |
|---|